Results 261 to 270 of about 90,317 (313)

pH-Responsive mPEG-PLGA/Dexamethasone Coatings for Corrosion Control and Osteo-Immune Modulation of Biodegradable Magnesium. [PDF]

Polymers (Basel)
Kim YK, Kim SY, Jang YS, Lee MH.
europepmc   +1 more source

Chemomechanical remodeling of glucocorticoid-sensitive fibroblasts for multimodal synergistic therapy of skin fibrosis. [PDF]

Cell Rep Med
Lu Y, Yang P, Gou W, Wang Y, Ran L, Shi L, Qin Y, Li J, Zhang N, Xue D, Ao M, Shu Z, Zhang X, Zhou Y, Huang L, He D, Zhang X, Huang Y, Li H, Zhou J, Tan J, Zhang Q, Luo G.   +22 more
europepmc   +1 more source

Integrating BMSC-inlaid GelMA hydrogels and melatonin-loaded PLGA microspheres into silk fibroin/nanohydroxyapatite scaffolds to repair osteoporotic bone defects. [PDF]

J Orthop Surg Res
Lv J, Ma B, Li J, Wang Z.
europepmc   +1 more source

Conjugation of a Cryptococcus neoformans-derived metalloprotease to antifungal-loaded PLGA nanoparticles treats neural cryptococcosis in an in vitro model. [PDF]

PLoS One
Lanser DM, Turner A, Pacifici N, Vu K, Lewis J, Gelli A.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation

Journal of Controlled Release, 2019
Injectable, long-acting depot formulations based on poly(lactide-co-glycolide) (PLGA) have been used clinically since 1989. Despite 30 years of development, however, there are only 19 different drugs in PLGA formulations approved by the U.S. Food and Drug Administration (FDA). The difficulty in developing depot formulations stems in large part from the
Kinam Park, Sarah Skidmore, John Garner
exaly   +3 more sources

Platelet Compatibility of PLGA, Chitosan and PLGA–Chitosan Nanoparticles

Nanomedicine, 2009
The increasing interest in biodegradable nanoparticles containing biomaterials such as poly(D,L-lactide-co-glycolide) (PLGA) and chitosan for drug delivery raises issues regarding the blood compatibility of these nanoparticles, since some nanoparticles, including carbon nanoparticles, can affect human platelet aggregation and cause vascular thrombosis.
Xue, Li, Anna, Radomski, Owen I, Corrigan, Lidia, Tajber, Fabio, De Sousa Menezes, Sibylle, Endter, Carlos, Medina, Marek W, Radomski   +7 more
openaire   +2 more sources

PLGA Microspheres Encapsulating siRNA

2014
The therapeutic use of small interfering RNA (siRNA) represents a new and powerful approach to suppress the expression of pathologically genes. However, biopharmaceutical drawbacks, such as short half-life, poor cellular uptake, and unspecific distribution into the body, hamper the development of siRNA-based therapeutics.
DE ROSA, GIUSEPPE, SALZANO, GIUSEPPINA
openaire   +3 more sources